pubmed-article:12917462 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0019733 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0524637 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0003316 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0439064 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0439662 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C2698650 | lld:lifeskim |
pubmed-article:12917462 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
pubmed-article:12917462 | pubmed:issue | Pt 9 | lld:pubmed |
pubmed-article:12917462 | pubmed:dateCreated | 2003-8-14 | lld:pubmed |
pubmed-article:12917462 | pubmed:abstractText | MHC-I-restricted cytotoxic responses are considered a critical component of protective immunity against viruses, including human immunodeficiency virus type 1 (HIV-1). CTLs directed against accessory and early regulatory HIV-1 proteins might be particularly effective; however, CTL epitopes in these proteins are rarely found. Novel artificial neural networks (ANNs) were used to quantitatively predict HLA-A2-binding CTL epitope peptides from publicly available full-length HIV-1 protein sequences. Epitopes were selected based on their novelty, predicted HLA-A2-binding affinity and conservation among HIV-1 strains. HLA-A2 binding was validated experimentally and binders were tested for their ability to induce CTL and IFN-gamma responses. About 69 % were immunogenic in HLA-A2 transgenic mice and 61 % were recognized by CD8(+) T-cells from 17 HLA-A2 HIV-1-positive patients. Thus, 31 novel conserved CTL epitopes were identified in eight HIV-1 proteins, including the first HLA-A2 minimal epitopes ever reported in the accessory and regulatory proteins Vif, Vpu and Rev. Interestingly, intermediate-binding peptides of low or no immunogenicity (i.e. subdominant epitopes) were found to be antigenic and more conserved. Such epitope peptides were anchor-optimized to improve immunogenicity and further increase the number of potential vaccine epitopes. About 67 % of anchor-optimized vaccine epitopes induced immune responses against the corresponding non-immunogenic naturally occurring epitopes. This study demonstrates the potency of ANNs for identifying putative virus CTL epitopes, and the new HIV-1 CTL epitopes identified should have significant implications for HIV-1 vaccine development. As a novel vaccine approach, it is proposed to increase the coverage of HIV variants by including multiple anchor-optimized variants of the more conserved subdominant epitopes. | lld:pubmed |
pubmed-article:12917462 | pubmed:language | eng | lld:pubmed |
pubmed-article:12917462 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:12917462 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:12917462 | pubmed:month | Sep | lld:pubmed |
pubmed-article:12917462 | pubmed:issn | 0022-1317 | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:BrunakSørenS | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:MathiesenLars... | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:ChaplinPaulP | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:FomsgaardAnde... | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:KronborgGitte... | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:BuusSørenS | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:VinnerLasseL | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:CorbetSylvieS | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:NielsenHenrik... | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:LauemollerSan... | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:TherrienDomin... | lld:pubmed |
pubmed-article:12917462 | pubmed:author | pubmed-author:TangSheilaS | lld:pubmed |
pubmed-article:12917462 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:12917462 | pubmed:volume | 84 | lld:pubmed |
pubmed-article:12917462 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:12917462 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:12917462 | pubmed:pagination | 2409-21 | lld:pubmed |
pubmed-article:12917462 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:meshHeading | pubmed-meshheading:12917462... | lld:pubmed |
pubmed-article:12917462 | pubmed:year | 2003 | lld:pubmed |
pubmed-article:12917462 | pubmed:articleTitle | Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. | lld:pubmed |
pubmed-article:12917462 | pubmed:affiliation | Department of Virology, Statens Serum Institut, 5 Artillerivej, DK-2300 Copenhagen S, Denmark. | lld:pubmed |
pubmed-article:12917462 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:12917462 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12917462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12917462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12917462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12917462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12917462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12917462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12917462 | lld:pubmed |